Added to YB: 2026-09-29
Pitch date: 2026-09-24
RARE [bullish]
Ultragenyx Pharmaceutical Inc.
+2.02%
current return
Author Info
Kelin Research shares independent research on listed life sciences companies. I work from primary sources, clinical data and back-of-the-envelope valuation to answer three questions: what does the science say, what is the market pricing in, and what would prove or kill the thesis? Sign up for the newsletter.
Company Info
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Market Cap
$1.4B
Pitch Price
$14.87
Price Target
24.00 (+58%)
Dividend
N/A
EV/EBITDA
-4.73
P/E
-2.49
EV/Sales
3.07
Sector
Biotechnology
Category
special_situation
Update Thoughts on Ultragenyx RARE
RARE (hold): Ultragenyx offers a relatively cheap entry into commercial gene therapy after Fayuvi’s approval removed the PDUFA binary, but rerating requires successful Fayuvi and Genglycos launches plus execution of cost cuts toward 2027 profitability. Monetizing two transferable priority-review vouchers for an estimated $350-400M gross could support an initial move from $14.88 to $18-20; the broader scenario remains $24 upside versus $13 downside, with execution confidence only moderate.
Read full article (3 min)